Why Pharma Risk Registers Misclassify Their Biggest Third-Party Exposures

Article excerpt

Pharmaceutical companies' risk management systems routinely miscategorize their biggest third-party vendor exposures, classifying them based on which department suffers the most visible consequences rather than where governance actually broke down. This mislabeling obscures the true sources of vulnerability in pharma supply chains and regulatory compliance frameworks. By tagging problems according to symptom rather than root cause, a manufacturing delay versus the vendor oversight failure that allowed it, companies create blind spots in their risk architecture. The article argues pharma should instead trace incidents backward to identify governance gaps, ensuring risk registers reflect where control systems failed. This reframing would strengthen third-party management across an industry where supply chain disruptions carry enormous stakes: patient safety, regulatory compliance, and operational continuity.